

DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS

Reporting period: 2022
Date of publication: June 30, 2023

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier <i>OPTIONAL</i>	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy		TOTAL <i>OPTIONAL</i>		
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract			
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
	Dr. Giannis Mountzios	Athens	Greece	2nd Oncology Department and Clinical Trials Unit HENRY DUNANT Hospital Center - 107 Mesogeion Ave		N/A	N/A			1.200 EUR		N/A	1.200 EUR	
	0													
	Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A			1.200 EUR		N/A	1.200 EUR
	Number of Recipients in aggregate disclosure						N/A	N/A			1		N/A	
	% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A			50%		N/A	50%
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
												N/A		
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>													
	Aggregate amount attributable to transfers of value to such Recipients												N/A	
	Number of Recipients in aggregate disclosure												N/A	
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed												N/A		
R&D	AGGREGATE DISCLOSURE													
	Transfers of Value re Research & Development as defined in the EFPIA Code of Practice											263.544 EUR		